Literature DB >> 14639612

Can cervical cancer screening be stopped at 50? The prevalence of HPV in elderly women.

Marc F D Baay1, Evelien Smits, Wiebren A A Tjalma, Filip Lardon, Joost Weyler, Paul Van Royen, Eric A E Van Marck, Jan B Vermorken.   

Abstract

Although the relation between cervical cancer and the human papillomavirus (HPV) has been established beyond doubt, the introduction of HPV detection in cervical cancer screening is halted, primarily by the high rate of false positivity in relation to morbidity, since the majority of women infected with HPV will not develop lesions. To counteract overconsumption of cervical cancer screening in elderly women, we wanted to test the hypothesis that women of 50 years or older who are HPV-negative and have a cytologically normal smear might be encouraged to refrain from further screening. As a first step, the prevalence of high-risk HPV in a population of 1,936 women of 50 years and older was investigated. After an initial decline, a slightly higher prevalence can be seen with increasing age. There is a decrease in the prevalence of multiple infections with age, paralleled by an increase in single infections, especially of HPV type 16 in the eldest-age group. However, neither the decrease in multiple infections nor the increase in single infections is statistically significant. The data obtained in this study show that, even in the presence of a slight increase in the HPV prevalence in elderly women, approximately 94% of the elderly women can be withdrawn from the cervical cancer screening. However, a follow-up study will be necessary to determine the frequency of (re)infection as well as the course of an HPV infection in elderly women. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14639612     DOI: 10.1002/ijc.11543

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  5 in total

1.  Concomitant Chlamydia trachomatis and human papilloma virus infection cannot be attributed solely to sexual behaviour.

Authors:  V Verhoeven; M Baay; J Weyler; D Avonts; F Lardon; P Van Royen; J B Vermorken
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-08-18       Impact factor: 3.267

2.  Evidence for cervical cancer mortality with screening program in Taiwan, 1981-2010: age-period-cohort model.

Authors:  Shih-Yung Su; Jing-Yang Huang; Chien-Chang Ho; Yung-Po Liaw
Journal:  BMC Public Health       Date:  2013-01-08       Impact factor: 3.295

3.  Cervical human papillomavirus screening among older women.

Authors:  Matthew J Grainge; Rashmi Seth; Li Guo; Keith R Neal; Carol Coupland; Paul Vryenhoef; Jane Johnson; David Jenkins
Journal:  Emerg Infect Dis       Date:  2005-11       Impact factor: 6.883

4.  Incidence of cervical cancer after several negative smear results by age 50: prospective observational study.

Authors:  Matejka Rebolj; Marjolein van Ballegooijen; Elsebeth Lynge; Caspar Looman; Marie-Louise Essink-Bot; Rob Boer; Dik Habbema
Journal:  BMJ       Date:  2009-04-24

5.  Value of high-risk human papillomavirus 16 deoxyribonucleic acid testing with cytological entities in peri and postmenopausal women.

Authors:  Veena Kashyap; Suresh Hedau
Journal:  J Cytol       Date:  2013-07       Impact factor: 1.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.